Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    Empagliflozin
Show Display Options
Rank Status Study
1 Recruiting Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Condition: Non Alcoholic Fatty Liver Disease
Intervention: Drug: Empagliflozin
2 Completed Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo
3 Recruiting Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
Conditions: Diabetes Mellitus, Type 2;   Diastolic Dysfunction
Interventions: Drug: Empagliflozin;   Drug: Placebo
4 Recruiting Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Empagliflozin and Linagliptin;   Drug: Metformin and Insulin sc
5 Completed Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Linagliptin;   Other: Placebo;   Drug: Empagliflozin
6 Recruiting Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Conditions: Type 2 Diabetes;   Non-alcoholic Fatty Liver Disease
Interventions: Drug: Empagliflozin;   Drug: Placebo
7 Recruiting Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin;   Drug: Placebo (matching empagliflozin);   Drug: ramipril
8 Not yet recruiting The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Conditions: Type2 Diabetes;   NAFLD
Intervention: Drug: Empagliflozin
9 Completed Empa/Lina FDC Food Effect Study (Japan)
Condition: Healthy
Intervention: Drug: empagliflozin/linagliptin FDC
10 Completed
Has Results
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Metformin
11 Not yet recruiting Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Conditions: Hypertension;   Type II Diabetes
Interventions: Drug: empagliflozin;   Drug: Metformin
12 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
13 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
14 Recruiting JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
15 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Linagliptin
16 Not yet recruiting Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Empagliflozin 25mg;   Drug: Lobeglitazone 0.5mg;   Drug: Empagliflozin 25mg/Lobeglitazone 0.5mg
17 Recruiting The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo
18 Not yet recruiting SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Behavioral: Diet;   Drug: Placebo
19 Completed
Has Results
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: BI 10773
20 Completed
Has Results
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin medium placebo;   Drug: Empagliflozin low placebo;   Drug: Empagliflozin high placebo;   Drug: Empagliflozin medium;   Drug: Empagliflozin low;   Drug: Empagliflozin high

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.